



[Notes to editors]

1. About the Global Health Innovative Technology Fund (GHIT Fund)

The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization aimed to advance the research and development (R&D) of new health technologies from Japan to fight infectious diseases prevalent specifically in the developing world, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases (NTDs). Established as a public-private partnership between the Government of Japan, a consortium of pharmaceutical companies and the Bill & Melinda Gates Foundation, the GHIT Fund facilitates and funds the R&D of new health technologies through partnership creation and grant-making activities. To learn more about the GHIT Fund, please see www.ghitfund.org.

2. About Neglected Tropical Diseases (NTDs)

Over 1 billion people live in the poorest 2.7 billion people. There are 149 countries and territories where NTDs are endemic, at least 100 of which are endemic for 2 or more of these diseases, and 30 countries that are endemic for 6 or more. These diseases not only survive and spread in conditions of poverty; they also anchor large populations in poverty.

* NTDs designated by the WHO for control or elimination: Buruli ulcer, Chagas disease (American trypanosomiasis), cysticercosis/taeniasis, dengue / severe dengue, dracunculiasis (Guinea worm disease), echinococcosis, fascioliasis, human African trypanosomiasis, leishmaniasis, leprosy, lymphatic filariasis, onchocerciasis, rabies, schistosomiasis, soil-transmitted helminthiasis, trachoma, and yaws

3. About Eisai's Commitment to Improving Global Access to Medicines

Today, it is estimated that some 2.7 billion people around the world live on US\$2 or less per day. Most of these 2.7 billion people do not have access to essential healthcare and treatment despite the availability of effective medicines. This is an international challenge that needs to be solved through collaborations among governments, international organizations such as the World Health Organization (WHO), non-governmental organizations, and pharmaceutical companies. In line with its *human health care (hhc)* mission, Eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities, and non-profit organizations. As part of these efforts, the company has agreed to provide the medicine diethylcarbamazine (DEC) free of charge to the WHO in support of its program to eliminate the NTD lymphatic filariasis, and is also engaged in a research collaboration with an international non-profit foundation to develop the new drug E1224 (a prodrug of ravuconazole) for the treatment of Chagas disease. For more information, please visit the Eisai's Medicines page on the Eisai global website: <http://www.eisai.com/company/atm/index.html>.